Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  ISIS Pharmaceuticals, Inc.    ISIS   US4643301090

 SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/27/2014 10/28/2014 10/29/2014 10/30/2014 10/31/2014 Date
45.86(c) 46.43(c) 45.01(c) 45.88(c) 46.71 Last
1 919 246 2 962 078 1 980 549 2 083 170 393 116 Volume
+1.91% +1.24% -3.06% +1.93% +1.81% Change
More quotes
Company
Isis Pharmaceuticals, Inc. engages in the development and commercialization of drugs to treat various health conditions, including inflammatory, viral, metabolic and cardiovascular and dermatological diseases and cancer.The company operates in two segments: Drug Discovery & Development and... 
Sector
Biotechnology & Medical Research
Calendar
11/06 | 09:30amPresentation
Surperformance© rating of ISIS Pharmaceuticals, Inc.
Trading Rating : Investor Rating :
More about the company
Chart ISIS PHARMACEUTICALS, INC.
Duration : Period :
ISIS Pharmaceuticals, Inc. Technical Analysis Chart | ISIS | US4643301090 | 4-Traders
Full-screen chart
Financials ($)
Sales 2014 178 M
EBIT 2014 -75,0 M
Net income 2014 -88,9 M
Debt 2014 209 M
Yield 2014 -
Sales 2015 162 M
EBIT 2015 -110 M
Net income 2015 -137 M
Debt 2015 57,1 M
Yield 2015 -
PER 2014 -
PER 2015
EV / Sales 2014 31,4x
EV / Sales 2015 33,7x
Capitalization 5 402 M
More Financials
Latest news on ISIS PHARMACEUTICALS, INC.
3h ago ISIS PHARMACEUTICALS' : Third Quarter 2014 Financial Results Conference Call (We..
1d ago ISIS PHARMACEUTICALS : to Present at the Nomura Biotechnology Conference
3d ago ISIS PHARMACEUTICALS : Assigned Patent
10/10 ISIS PHARMACEUTICALS : Reports Data From ISIS-SMN Rx Phase 2 Studies in Infants ..
10/09 GLAXOSMITHKLINE : Isis Pharma Earns USD18 Million From GSK For Advancing ISIS-TT..
10/09 ISIS PHARMACEUTICALS : Earns $18 Million From GSK for Advancing ISIS-TTR Rx
10/08 ISIS PHARMACEUTICALS : "Compounds and Methods for Modulating Protein Expression"..
10/02 ISIS PHARMACEUTICALS : to Host Webcast to Discuss ISIS-SMN Rx Results Presented ..
10/01 Isis Pharma Earns USD1.5 Million From Glaxo For ISIS-GSK4 Rx
10/01 ISIS PHARMACEUTICALS : Earns $1.5 Million From GSK for the Advancement of ISIS-G..
09/24 ISIS PHARMACEUTICALS : Earns $4 Million from Achaogen for the Initiation of a Ph..
09/24 ISIS PHARMACEUTICALS : to Present at the Leerink Partners Rare Disease Roundtabl..
More news
4-Traders Strategies on ISIS PHARMACEUTICALS, INC. 
08/14A resistance as obstacle
More Strategies


Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF